Table of Contents
Can sorafenib cure cancer?
Sorafenib is a new multikinase inhibitor, which has been shown to exhibit a significant anticancer effect in the treatment of solid tumors. It has been approved for the treatment of advanced RCC, and was recently found to improve survival of patients with advanced HCC as compared to placebo when used as monotherapy.
What are the side effects of sorafenib?
Side Effects
- Bleeding gums.
- blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet.
- bloating of the abdomen or stomach.
- blood in the urine or stools.
- clay-colored stools.
- coughing up blood.
- difficulty with breathing or swallowing.
- increased menstrual flow or vaginal bleeding.
Is sorafenib considered chemotherapy?
Sorafenib (Nexavar) Chemotherapy Drug Information.
Can you drink alcohol on sorafenib?
The drinking of alcohol (in small amounts) does not appear to affect the safety or usefulness of sorafenib. plan to have children, discuss this with your doctor before being treated with sorafenib. best to use birth control while being treated with sorafenib.
Is sorafenib a chemotherapy?
Nexavar (sorafenib) is a cancer (chemotherapeutic) medication used to treat a type of kidney cancer called advanced renal cell carcinoma. Nexavar is also used to treat liver cancer.
Can HCC be reversed?
Since HCC usually grows slowly in its early stages, it can often be cured if discovered early enough.
What is sorafenib target?
Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the treatment of advanced renal cell carcinoma in 2006, and as a unique target drug for advanced hepatocellular carcinoma (HCC) in 2007.
Does hepatocellular carcinoma spread quickly?
Liver cancer can spread quickly depending on the type of cancer. Hemangiosarcoma and angiosarcoma types of liver cancer are fast spreading, whereas hepatocellular carcinoma spreads late in the disease.
How long can you live with Stage 4 HCC?
In one small study of people with metastatic hepatocellular carcinoma, those whose liver cancer had spread to their lymph nodes or distant organs had an average survival rate of 4 and 11 months, depending on the severity of their liver damage and whether they received treatment.
What is the purpose of the sorafenib study?
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics (PK) in patients with liver cancer.
How many patients were screened for sorafenib in 2006?
From March 10, 2005, to April 11, 2006, we screened 902 patients. Of these patients, 602 met the eligibility criteria and underwent randomization, with 299 patients assigned to the sorafenib group and 303 patients assigned to the placebo group. These patients were all included in the intention-to-treat analysis ( Figure 1 ).
Is sorafenib effective for hepatocellular carcinoma?
Sorafenib is currently approved as the only systemic therapy for HCC. Sorafenib has been reported to provide no significant benefit in TTP or OS in selected HCC patients when administered after initial response to TACE [28].
What is the prognosis of sorafenib toxicity?
At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001).